Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial - Quiz - MDSpire

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

  • By

  • Lee M. Kaplan

  • Elena Startseva

  • Carel W. le Roux

  • Sean Wharton

  • Biykem Bozkurt

  • Daniel F. Mazo

  • Jessica von Schlippenbach

  • Sandra González Maldonado

  • Samina Ajaz Hussain

  • Guy W. Neff

  • Yaneicy Gonzalez Rojas

  • Charles Smith

  • Ramy Younes

  • Arun J. Sanyal

  • June 7, 2026

  • 0 min

Share

Original Source(s)

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

  • by Lee M. Kaplan, Elena Startseva, Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Daniel F. Mazo, Jessica von Schlippenbach, Sandra González Maldonado, Samina Ajaz Hussain, Guy W. Neff, Yaneicy Gonzalez Rojas, Charles Smith, Ramy Younes, Arun J. Sanyal

  • June 7, 2026

Related Content

Risk factors for postoperative adverse outcomes in patients with high anal fistula undergoing modified TROPIS procedure combined with Parks’ fistulotomy with seton: a retrospective study

Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review

Trained immunity as a systemic bridge: the liver-gut-immune-oral axis in the comorbidity of chronic liver disease and periodontitis